Keybanc analyst Thomas Blakey maintains Globant (NYSE:GLOB) with a Overweight and lowers the price target from $291 to $232.
Bicycle Therapeutics Announces Publication Of Article Highlighting Preclinical Data From BT8009 Program In Molecular Cancer Therapeutics
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that an